NZ701133A - Composition for treating metabolic disorders - Google Patents
Composition for treating metabolic disordersInfo
- Publication number
- NZ701133A NZ701133A NZ701133A NZ70113313A NZ701133A NZ 701133 A NZ701133 A NZ 701133A NZ 701133 A NZ701133 A NZ 701133A NZ 70113313 A NZ70113313 A NZ 70113313A NZ 701133 A NZ701133 A NZ 701133A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- metabolic disorders
- relates
- extract
- treating metabolic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636792P | 2012-04-23 | 2012-04-23 | |
| PCT/IB2013/053155 WO2013160811A1 (en) | 2012-04-23 | 2013-04-22 | Composition for treating metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701133A true NZ701133A (en) | 2016-08-26 |
Family
ID=49482298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701133A NZ701133A (en) | 2012-04-23 | 2013-04-22 | Composition for treating metabolic disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150290265A1 (enExample) |
| EP (1) | EP2841080A4 (enExample) |
| JP (1) | JP2015514797A (enExample) |
| KR (1) | KR20150003862A (enExample) |
| CN (1) | CN104244962A (enExample) |
| AU (1) | AU2013254329A1 (enExample) |
| BR (1) | BR112014026326A2 (enExample) |
| CA (1) | CA2870907A1 (enExample) |
| IL (1) | IL235317A0 (enExample) |
| IN (1) | IN2014MN02269A (enExample) |
| MX (1) | MX2014012742A (enExample) |
| NZ (1) | NZ701133A (enExample) |
| RU (1) | RU2014145931A (enExample) |
| SA (1) | SA113340494B1 (enExample) |
| TW (1) | TW201343174A (enExample) |
| WO (1) | WO2013160811A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3233188A4 (en) * | 2014-12-19 | 2018-11-07 | Halo Life Science, LLC | Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| MX2020007394A (es) | 2018-01-10 | 2020-09-03 | Brightseed Inc | Metodo para modular el metabolismo. |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| KR20220100896A (ko) | 2019-11-11 | 2022-07-18 | 브라이트씨드, 인크. | 추출물, 소모가능 생성물 및 추출물에서 생물활성 대사산물을 농후화하는 방법 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| KR102408566B1 (ko) * | 2020-04-09 | 2022-06-16 | 대한민국 | 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물 |
| JP2023144436A (ja) * | 2022-03-28 | 2023-10-11 | 住友化学株式会社 | エラグ酸含有組成物の製造方法及びエラグ酸含有組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053864A (ja) * | 2003-08-06 | 2005-03-03 | Ryukyu Bio Resource Kaihatsu:Kk | 糖尿病疾患予防・治療剤 |
| JP2006188486A (ja) * | 2004-12-07 | 2006-07-20 | Toyo Shinyaku:Kk | 体脂肪蓄積抑制または低減剤 |
| AP2007004162A0 (en) * | 2005-02-23 | 2007-10-31 | Avestha Gengraine Tech Pvt Ltd | Plant extracts and methods and uses therefore |
-
2013
- 2013-04-22 IN IN2269MUN2014 patent/IN2014MN02269A/en unknown
- 2013-04-22 BR BR112014026326A patent/BR112014026326A2/pt not_active IP Right Cessation
- 2013-04-22 NZ NZ701133A patent/NZ701133A/en not_active IP Right Cessation
- 2013-04-22 EP EP13781126.1A patent/EP2841080A4/en not_active Withdrawn
- 2013-04-22 TW TW102114264A patent/TW201343174A/zh unknown
- 2013-04-22 CN CN201380021515.3A patent/CN104244962A/zh active Pending
- 2013-04-22 KR KR20147032772A patent/KR20150003862A/ko not_active Withdrawn
- 2013-04-22 AU AU2013254329A patent/AU2013254329A1/en not_active Abandoned
- 2013-04-22 CA CA 2870907 patent/CA2870907A1/en not_active Abandoned
- 2013-04-22 JP JP2015507634A patent/JP2015514797A/ja active Pending
- 2013-04-22 US US14/391,762 patent/US20150290265A1/en not_active Abandoned
- 2013-04-22 RU RU2014145931A patent/RU2014145931A/ru unknown
- 2013-04-22 MX MX2014012742A patent/MX2014012742A/es unknown
- 2013-04-22 WO PCT/IB2013/053155 patent/WO2013160811A1/en not_active Ceased
- 2013-04-23 SA SA113340494A patent/SA113340494B1/ar unknown
-
2014
- 2014-10-23 IL IL235317A patent/IL235317A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014MN02269A (enExample) | 2015-07-24 |
| MX2014012742A (es) | 2015-04-08 |
| US20150290265A1 (en) | 2015-10-15 |
| RU2014145931A (ru) | 2016-06-20 |
| SA113340494B1 (ar) | 2015-12-24 |
| EP2841080A4 (en) | 2015-11-25 |
| BR112014026326A2 (pt) | 2017-06-27 |
| TW201343174A (zh) | 2013-11-01 |
| AU2013254329A1 (en) | 2014-11-13 |
| IL235317A0 (en) | 2014-12-31 |
| CA2870907A1 (en) | 2013-10-31 |
| EP2841080A1 (en) | 2015-03-04 |
| WO2013160811A1 (en) | 2013-10-31 |
| KR20150003862A (ko) | 2015-01-09 |
| JP2015514797A (ja) | 2015-05-21 |
| CN104244962A (zh) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA113340494B1 (ar) | تركيبة لعلاج اضطرابات أيضية | |
| MX2018000421A (es) | Composiciones de retinoides topicos. | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| HK1210599A1 (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| HK1201828A1 (en) | Treatment regimens using multiple pharmaceutical agents | |
| EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| WO2014102483A3 (fr) | Composition cosmetique ou dermatologique a base d'extraits d'iris et son utilisation | |
| MX2022014763A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| EP4302825A3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| GB2525517A (en) | Topical preparation for pain relief | |
| MY160160A (en) | Anti-wart pharmaceutical composition and method for treating wart | |
| WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
| IN2014MN01933A (enExample) | ||
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| WO2014116015A3 (ko) | 자죽염을 포함하는 알츠하이머병 예방용 조성물 및 자죽염의 제조방법 | |
| WO2012108748A3 (ko) | 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물 | |
| WO2013038200A3 (en) | Neurodevelopmental disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2018 BY JAMES + WELLS Effective date: 20170411 |
|
| LAPS | Patent lapsed |